HCPCS E0483 (high-frequency chest wall oscillation vest): commercial payer coverage 2026
Which US commercial payers cover a high-frequency chest wall oscillation (HFCWO) vest billed as HCPCS E0483, and on what criteria. One row per payer, with the policy number, the stated date, a short coverage summary, a verbatim quote, and a link to the payer’s own policy.
Last checked 2026-10-13. Sources are each payer's own public document. Where a payer has no readable public policy, this page says "could not verify" rather than guess a stance.
- No patient data
- No BAA
- No charge
- No pitch
What E0483 is
E0483 is the high-frequency chest wall oscillation (HFCWO) system code. Its long descriptor was revised on 2022-10-01. A7025 and A7026 are the replacement vest and hose codes.
E0469 is a separate code for oscillation and lung expansion devices; it is not covered here.
Most reviewed commercial payers cover HFCWO with clinical criteria for cystic fibrosis and CT-confirmed bronchiectasis. They split on neuromuscular disease: several Blue Cross plans that follow the BCBSA reference policy call that use investigational or not medically necessary.
Commercial payer coverage of E0483
15 payers with a verified stance, 3 that could not be verified. Each stance is the payer's own wording. Click a source to read the policy.
| Payer | Stance on E0483 | Date stated | Covered conditions (short) | Source |
|---|---|---|---|---|
| UnitedHealthcare Commercial + Individual Exchange | Covered with criteria (2-month rental trial) | Effective 03/01/2026 | CF, bronchiectasis, neuromuscular; rental trial | uhcprovider.com (PDF) |
| Aetna Commercial | Covered with criteria (in lieu of chest physiotherapy) | Last review 03/18/2026. Next review 01/14/2027. | CF, bronchiectasis, neuromuscular, transplant | aetna.com CPB 0067 |
| Cigna Commercial (no delegated vendor named) | Covered with criteria | Effective 11/09/2025. Next review date 10/15/2026. | CF, bronchiectasis, neuromuscular (with failure) | static.cigna.com 0069 (PDF) |
| Elevance / Anthem Commercial (plan-by-plan adoption not verified) | Covered with criteria | Last review 11/06/2025. Published 01/06/2026. | CF, bronchiectasis, neuromuscular (with failure) | anthem.com CG-DME-43 |
| Centene / Ambetter Commercial | Not addressed by a device-specific policy | CP.MP.107: Date of last revision 08/26 | General DME criteria only; E0483 not listed | ambetterhealth.com CP.MP.107 (PDF) |
| Humana Commercial | No current commercial policy | n/a | No current commercial policy | See Medicare LCD L33785 for context |
| Kaiser Permanente (Washington) Commercial (Washington region, non-Medicare) | Covered with criteria (the strictest found) | Last revised 07/17/2025. Criteria change effective 07/01/2025. | CF, bronchiectasis, neuromuscular; strict criteria | wa-provider.kaiserpermanente.org (PDF) |
| Kaiser Permanente (Mid-Atlantic States) Commercial (Mid-Atlantic region) | Covered with criteria (cough reflex required) | Last approved 09/26/2024 | CF, PCD, bronchiectasis, neuromuscular | healthy.kaiserpermanente.org (PDF) |
| Premera Blue Cross Commercial (WA/AK) | CF & bronchiectasis only; neuromuscular not medically necessary | Effective 11/01/2025. Last revised 10/13/2025. | CF & bronchiectasis only; neuromuscular denied | premera.com (PDF) |
| Blue Shield of California Commercial | CF & bronchiectasis only; neuromuscular investigational | Effective 11/01/2025 (annual review, no change) | CF & bronchiectasis only; neuromuscular investigational | blueshieldca.com (PDF) |
| BCBS Federal Employee Program Commercial (FEHB, BCBSA) | CF & bronchiectasis only; neuromuscular investigational | Annual effective policy date 01/01/2026 | CF & bronchiectasis only; neuromuscular investigational | fepblue.org (PDF) |
| BCBS Kansas Commercial | CF, bronchiectasis, cerebral palsy; neuromuscular E/I | Latest review 09/23/2025. Current effective date 08/17/2018. | CF, bronchiectasis, cerebral palsy; neuromuscular E/I | bcbsks.com |
| Highmark Commercial (PA) | Covered with criteria (incl. neuromuscular) | Effective 11/10/2025. Last revision September 2025. | CF, bronchiectasis, neuromuscular (with failure) | highmark.com E-68-019 |
| Excellus BCBS Commercial (NY) | Covered with criteria (incl. neuromuscular) | Effective 03/16/2026 (committee approval 11/20/25) | CF, ciliary dyskinesia, neuromuscular, bronchiectasis | excellusbcbs.com (PDF) |
| Wellmark BCBS Commercial (IA/SD) | Covered with criteria (incl. neuromuscular) | Review date September 2025. Revised September 2024. | CF, bronchiectasis, neuromuscular (with failure) | wellmark.com (PDF) |
| BCBS Michigan Commercial | Could not verify | n/a | Could not verify | No public policy found |
| Kaiser Permanente (Northern California) Commercial | Could not verify | n/a | Could not verify | No public policy found |
| Kaiser Permanente (Southern California) Commercial | Could not verify | n/a | Could not verify | No public policy found |
Regence, Blue Cross NC "Oscillatory Devices for Treatment of Respiratory Conditions" and HCSC (BCBS Texas DME101.027 and the BCBS Illinois copy) return HTTP 403/406 and could not be read, so their stance is not verified.
What each payer says
The quote is the payer's own, verbatim and under 30 words, linked to the source. The classification is the payer's, not ours.
UnitedHealthcare Covered with criteria (2-month rental trial)
Airway Clearance Devices, 2026T0052OO. Effective 03/01/2026.
“A 2-month rental trial of a high-frequency chest wall oscillation (HFCWO) system is proven and medically necessary in the management of neuromuscular diseases, Bronchiectasis, and cystic fibrosis”
UnitedHealthcare, uhcprovider.com (PDF)
All other conditions are unproven / not medically necessary. The detailed criteria are in InterQual, which sits behind a link and was not reviewed. Bronchiectasis requires CT confirmation. Ongoing use after the trial is decided by InterQual.
Aetna Covered with criteria (in lieu of chest physiotherapy)
CPB 0067, Chest Physiotherapy and Airway Clearance Devices. Last review 03/18/2026. Next review 01/14/2027..
“Aetna considers high-frequency chest compression systems ... medically necessary DME in lieu of chest physiotherapy ... where there is a well documented failure of standard treatments to adequately mobilize retained secretions”
Aetna, aetna.com CPB 0067
Bronchiectasis (CT) with daily productive cough for 6 months or more than 2 antibiotic-treated exacerbations per year; cystic fibrosis or immotile cilia syndrome; a listed neuromuscular diagnosis; lung transplant recipients in the first 6 months post-op. Other listed indications are experimental / investigational. SmartVest is a named example device.
Cigna Covered with criteria
Medical Coverage Policy 0069, Airway Clearance Devices in the Ambulatory Setting. Effective 11/09/2025. Next review date 10/15/2026..
“A high-frequency chest wall compression device (HCPCS E0483) is considered medically necessary for ANY of the following conditions”
Cigna, static.cigna.com 0069 (PDF)
Cystic fibrosis, CT-confirmed bronchiectasis, or chronic neuromuscular disease, each with documented failure of standard treatment and of a standard airway clearance device. Any other indication is not medically necessary. Update 2026-10-19: a new version effective 10/15/2026 added a primary ciliary dyskinesia statement; the E0483 criteria did not change.
Elevance / Anthem Covered with criteria
CG-DME-43, High Frequency Chest Compression Devices for Airway Clearance. Last review 11/06/2025. Published 01/06/2026..
“High frequency chest compression devices (see index for examples) are considered medically necessary when ALL of the following are met”
Elevance / Anthem, anthem.com CG-DME-43
Cystic fibrosis, chronic bronchiectasis, or a chronic neuromuscular disorder, plus documented failure of other airway clearance therapies and a compliance trial. Continued use needs compliance every 6 to 12 months. Not medically necessary when criteria are not met, or for replacement/upgrade for convenience. SmartVest is in the device index.
Centene / Ambetter Not addressed by a device-specific policy
CP.MP.107, Durable Medical Equipment and Orthotics and Prosthetics Guidelines. CP.MP.107: Date of last revision 08/26.
No E0483-specific policy found. The general DME policy CP.MP.107 does not list E0483; only the general DME criteria (necessary and reasonable, member education, a device trial with demonstrated ability to use it) are public. CP.MP.107 lists E0469 and home IPV as not medically necessary, but not E0483.
Humana No current commercial policy
None (Humana exited employer-group commercial medical in 2025). n/a.
Humana finished leaving the employer-group commercial medical business in 2025 (exit announced 02/23/2023). Not researched further in the snapshot.
Kaiser Permanente (Washington) Covered with criteria (the strictest found)
Clinical Review Criteria: High-Frequency Chest Wall Oscillation Devices (HFCWO). Last revised 07/17/2025. Criteria change effective 07/01/2025..
“Well-documented failure of standard treatments to adequately mobilize retained secretions with all of the following: ... A pattern of hospitalizations at least annually or more”
Kaiser Permanente (Washington), wa-provider.kaiserpermanente.org (PDF)
Cystic fibrosis: pulmonologist-managed, demonstrated twice-daily chest physical therapy and flutter use. Bronchiectasis (CT) or neuromuscular disorder: failed standard treatment, a pattern of at least annual hospitalizations, a deteriorating condition, pulmonologist care, and a rental trial before purchase.
Kaiser Permanente (Mid-Atlantic States) Covered with criteria (cough reflex required)
Medical Coverage Policy: HFCWO and Airway Oscillating Devices. Last approved 09/26/2024.
“The patient has adequate physiological cough reflex; and”
Kaiser Permanente (Mid-Atlantic States), healthy.kaiserpermanente.org (PDF)
Cystic fibrosis, primary ciliary dyskinesia, bronchiectasis (CT), or a listed neuromuscular disease, plus failure/intolerance/contraindication to standard treatments, an adequate cough reflex, and no listed contraindication (19, including osteoporosis). COPD and chronic bronchitis without bronchiectasis are investigational.
Premera Blue Cross CF & bronchiectasis only; neuromuscular not medically necessary
1.01.539, Oscillatory Devices for Cystic Fibrosis and Other Respiratory Conditions. Effective 11/01/2025. Last revised 10/13/2025..
“The use of high frequency chest wall compression devices and IPV devices in ... respiratory conditions associated with neuromuscular disorders are considered not medically necessary”
Premera Blue Cross, premera.com (PDF)
Covered for cystic fibrosis or chronic diffuse bronchiectasis (CT) when standard chest physical therapy failed, is unavailable or not tolerated. Adjunct use and use in COPD are not medically necessary.
Blue Shield of California CF & bronchiectasis only; neuromuscular investigational
1.01.15, Oscillatory Devices for Cystic Fibrosis and Other Respiratory Conditions. Effective 11/01/2025 (annual review, no change).
“Other applications of high-frequency chest wall compression devices ... are considered investigational, including ... Respiratory conditions associated with neuromuscular disorders”
Blue Shield of California, blueshieldca.com (PDF)
Follows the BCBSA reference policy: cystic fibrosis or chronic diffuse bronchiectasis (CT), plus failed, unavailable or not tolerated chest physical therapy. COPD and adjunct use are investigational.
BCBS Federal Employee Program CF & bronchiectasis only; neuromuscular investigational
FEP 1.01.15, Oscillatory Devices for Cystic Fibrosis and Other Respiratory Conditions. Annual effective policy date 01/01/2026.
“... their use in other lung diseases such as chronic obstructive pulmonary disease or respiratory conditions associated with neuromuscular disorders, are considered investigational”
BCBS Federal Employee Program, fepblue.org (PDF)
Cystic fibrosis or chronic diffuse bronchiectasis (CT), when standard chest physical therapy has failed or is unavailable or not tolerated.
BCBS Kansas CF, bronchiectasis, cerebral palsy; neuromuscular E/I
Oscillatory Devices for Cystic Fibrosis and Other Respiratory Disorders. Latest review 09/23/2025. Current effective date 08/17/2018..
“High-frequency chest wall compression devices and intrapulmonary percussive ventilation (IPV) devices may be considered medically necessary in individuals with: ... cerebral palsy with lung disease and recurrent pulmonary infections”
BCBS Kansas, bcbsks.com
Cystic fibrosis, chronic diffuse bronchiectasis (CT), or cerebral palsy with lung disease and recurrent pulmonary infections, plus failed, unavailable or not tolerated standard chest physiotherapy. Neuromuscular disorders are experimental / investigational.
Highmark Covered with criteria (incl. neuromuscular)
E-68-019, High Frequency Chest Wall Oscillation Devices. Effective 11/10/2025. Last revision September 2025..
“There must be well-documented failure of standard treatments to adequately mobilize retained secretions or valid reasons why standard chest physiotherapy cannot be performed”
Highmark, highmark.com E-68-019
Cystic fibrosis; chronic diffuse bronchiectasis (CT) with failed, unavailable or not tolerated chest physical therapy; or a listed neuromuscular diagnosis with documented failure of standard treatments. Not medically necessary when criteria are not met.
Excellus BCBS Covered with criteria (incl. neuromuscular)
1.01.15, Airway Clearance Devices. Effective 03/16/2026 (committee approval 11/20/25).
“Documented failure of, contraindication to, or lack of available resources to administer standard treatments”
Excellus BCBS, excellusbcbs.com (PDF)
A documented diagnosis that impairs clearance (cystic fibrosis, ciliary dyskinesia, neuromuscular disorder, diffuse bronchiectasis), exacerbations with inability to clear mucus, and failure of standard treatments. Referral must come from a pulmonologist. COPD and adjunct use are investigational. Smart Vest is a named example device.
Wellmark BCBS Covered with criteria (incl. neuromuscular)
01.01.01, Airway Clearance Devices in the Home Setting. Review date September 2025. Revised September 2024..
“A neurodegenerative/neuromuscular disease with documented, associated respiratory muscle weakness or diaphragm paralysis”
Wellmark BCBS, wellmark.com (PDF)
Chronic diffuse bronchiectasis (CT), cystic fibrosis, or a neurodegenerative/neuromuscular disease with respiratory muscle weakness or diaphragm paralysis, plus documented failure of standard treatments and recurrent exacerbations. Smartvest is a named example device.
BCBS Michigan Could not verify
No public HFCWO policy found. n/a.
No public HFCWO policy was found in the public search tools used.
Kaiser Permanente (Northern California) Could not verify
No public HFCWO criteria found. n/a.
No public HFCWO criteria were found for this region.
Kaiser Permanente (Southern California) Could not verify
No public HFCWO criteria found. n/a.
No public HFCWO criteria were found for this region.
What changed recently
- UHC 2026T0052OO (effective 03/01/2026): the InterQual reference changed to "Airway or Secretion Clearance Devices (Custom) - UHG". The documentation list now asks for the specific device, initial trial vs ongoing request, recent imaging and comorbidities. "Failed standard treatments" became "treatments tried, failed, or contraindicated".
- Excellus 1.01.15 (approved 11/20/25, effective 03/16/2026) loosened its criteria: conservative treatment requirements changed from an "and" to an "or" statement, and HFCWO and IPV were split into separate statements.
- Anthem CG-DME-43 (review 11/06/2025, published 01/06/2026) added a member summary and revised formatting. The bigger change was 11/14/2024, when Anthem removed the FDA-clearance criterion.
- Cigna 0069 (effective 11/09/2025) revised only the IPV statement and formatting; the E0483 criteria did not change. Next review 10/15/2026. Kaiser Washington changed its criteria effective 07/01/2025 to the strictest set found. No change in stance at Aetna, Premera, Blue Shield of CA, FEP, BCBS Kansas or Wellmark.
Medicare covers HFCWO with criteria
Context only, not a commercial policy. DME MAC LCD L33785, High Frequency Chest Wall Oscillation Devices (CGS and Noridian), revision effective 10/01/2022, covers cystic fibrosis, CT-confirmed bronchiectasis, and a listed set of neuromuscular diseases.
“well-documented failure of standard treatments to adequately mobilize retained secretions”
CGS / Noridian, LCD L33785
Using both HFCWO and a mechanical in-exsufflation device (E0482) is not reasonable and necessary. Policy article A52494 holds the ICD-10 list (not opened in the snapshot).
Why these deny, and how the appeal works
No patient data. No BAA. No charge.
Most E0483 denials are not a flat no. They turn on a missing criterion: the diagnosis is not one the policy lists, the CT confirmation or the documented failure of standard chest physiotherapy is not in the file, or the request is for a neuromuscular indication that a Blue Cross plan excludes. An appeal has to answer the exact criterion with the record. Send us 90 days of denials, 4 columns, and you get back which E0483 lines are worth working and what they are worth. The first review is free.
Sources
Each payer's own public document, read on 2026-10-13. No logins, no click-through terms accepted. The stance wording is the payer's; we did not write it.
- UnitedHealthcare: Airway Clearance Devices, 2026T0052OO. uhcprovider.com (PDF)
- Aetna: CPB 0067, Chest Physiotherapy and Airway Clearance Devices. aetna.com CPB 0067
- Cigna: Medical Coverage Policy 0069, Airway Clearance Devices in the Ambulatory Setting. static.cigna.com 0069 (PDF)
- Elevance / Anthem: CG-DME-43, High Frequency Chest Compression Devices for Airway Clearance. anthem.com CG-DME-43
- Centene / Ambetter: CP.MP.107, Durable Medical Equipment and Orthotics and Prosthetics Guidelines. ambetterhealth.com CP.MP.107 (PDF)
- Humana: None (Humana exited employer-group commercial medical in 2025). See Medicare LCD L33785 for context
- Kaiser Permanente (Washington): Clinical Review Criteria: High-Frequency Chest Wall Oscillation Devices (HFCWO). wa-provider.kaiserpermanente.org (PDF)
- Kaiser Permanente (Mid-Atlantic States): Medical Coverage Policy: HFCWO and Airway Oscillating Devices. healthy.kaiserpermanente.org (PDF)
- Premera Blue Cross: 1.01.539, Oscillatory Devices for Cystic Fibrosis and Other Respiratory Conditions. premera.com (PDF)
- Blue Shield of California: 1.01.15, Oscillatory Devices for Cystic Fibrosis and Other Respiratory Conditions. blueshieldca.com (PDF)
- BCBS Federal Employee Program: FEP 1.01.15, Oscillatory Devices for Cystic Fibrosis and Other Respiratory Conditions. fepblue.org (PDF)
- BCBS Kansas: Oscillatory Devices for Cystic Fibrosis and Other Respiratory Disorders. bcbsks.com
- Highmark: E-68-019, High Frequency Chest Wall Oscillation Devices. highmark.com E-68-019
- Excellus BCBS: 1.01.15, Airway Clearance Devices. excellusbcbs.com (PDF)
- Wellmark BCBS: 01.01.01, Airway Clearance Devices in the Home Setting. wellmark.com (PDF)
- BCBS Michigan: No public HFCWO policy found. No public policy found
- Kaiser Permanente (Northern California): No public HFCWO criteria found. No public policy found
- Kaiser Permanente (Southern California): No public HFCWO criteria found. No public policy found
- Medicare (context): CMS Medicare Coverage Database, LCD L33785